Entresto, a New Panacea for Heart Failure?

@article{Khalil2018EntrestoAN,
  title={Entresto, a New Panacea for Heart Failure?},
  author={Peter Khalil and Ghazal Kabbach and Sarmad Said and Debabrata Mukherjee},
  journal={Cardiovascular \& hematological agents in medicinal chemistry},
  year={2018},
  volume={16 1},
  pages={
          5-11
        }
}
Heart Failure (HF) is one of the main healthcare burdens in the United States and in the world. Many drugs are approved and used in practice for management of this condition; including beta blockers, diuretics, aldosterone antagonists, Angiotensin Converting Enzyme Inhibitors (ACEI's), and Angiotensin Receptor Blockers (ARBs). Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor… 
4 Citations
New pharmacotherapy for heart failure with reduced ejection fraction
TLDR
A comprehensive review of the literature using keywords such as heart failure with reduced ejection fraction, angiotensin receptor, neprilysin inhibitor, and sodium glucose transporter was conducted within the National Centre for Biotechnology Information (NCBI) and Google Scholar databases.
Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis.
  • M. Gaudino, Irbaz Hameed, +10 authors S. Fremes
  • Medicine
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2020
TLDR
CABG appears to be the best therapy for iLVSD, although mainly based on observational data, and proves as the best revascularization strategy for mortality, cardiac death, MI and RR.
Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
TLDR
Takotsubo syndrome is an acute potentially reversible cardiac syndrome characterized by variable regional myocardial akinesia that cannot be attributed to a culprit coronary artery occlusion and sacubitril/valsartan is a novel and effective pharmacological agent for the treatment of patients with heart failure.
Drug-drug cocrystals: Opportunities and challenges
TLDR
The drug-drug cocrystals that reported in last decade are reviewed and shed light on the opportunities and challenges for the development of drug- drug cocrystal.